Claims for Patent: 8,933,120

Summary for Patent: 8,933,120

Title:	Enhanced bimatoprost ophthalmic solution
Abstract:	A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
Inventor(s):	Chang; Chin-Ming (Tustin, CA), Chang; James N. (Newport Beach, CA), Schiffman; Rhett M. (Laguna Beach, CA), Jordan; R. Scott (Trabuco Canyon, CA), Chang-Lin; Joan-En (Tustin, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	14/100,914
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,933,120
Patent Claims:	1. An ophthalmic composition comprising about 0.01%-0.015% w/v bimatoprost and about 0.02% w/v benzalkonium chloride. 2. The ophthalmic composition of claim 1, wherein the composition comprises about 0.01% w/v bimatoprost. 3. The ophthalmic composition of claim 1, wherein the composition comprises 0.01% w/v bimatoprost. 4. The ophthalmic composition of claim 1, wherein the composition comprises about 0.015% w/v bimatoprost. 5. The ophthalmic composition of claim 1, wherein the composition comprises 0.015% w/v bimatoprost. 6. The ophthalmic composition of claim 1, wherein the composition comprises 0.02% w/v benzalkonium chloride. 7. The ophthalmic composition of claim 1, wherein the composition further comprises dibasic sodium phosphate. 8. The composition of claim 1, wherein the first composition further comprises citric acid monohydrate. 9. The composition of claim 1, wherein the composition further comprises sodium chloride. 10. The composition of claim 1, wherein the first composition further comprises hydrochloric acid and sodium hydroxide to adjust the pH. 11. The composition of claim 1, wherein the composition further comprises water. 12. The composition of claim 1, wherein the first composition has a pH of about 7.3. 13. The composition of claim 1, wherein the composition comprises 0.01% w/v bimatoprost and 0.02% w/v benzalkonium chloride, and when applied to the eyes of a human patient suffering from elevated intraocular pressure, lowers intraocular pressure and results in less hyperemia than a second composition comprising 0.03% w/v bimatoprost and 0.005% w/v benzalkonium chloride. 14. The composition of claim 13, wherein the composition applied once daily lowers intraocular pressure as effectively as the second composition applied once daily. 15. The composition of claim 13, wherein the composition is applied to the eyes of a human patient suffering from elevated intraocular pressure at least once a day. 16. The composition of claim 13, wherein the composition applied once daily lowers intraocular pressure more effectively than the second composition applied once daily. 17. The composition method of claim 13, wherein the composition applied once daily is effective for treating glaucoma. 18. The composition of claim 1, wherein the composition comprises 0.01% w/v bimatoprost and 0.02% w/v benzalkonium chloride, and when applied once daily to the eyes of a human patient suffering from elevated intraocular pressure, lowers intraocular pressure and results in less hyperemia than a second composition comprising 0.03% w/v bimatoprost and 0.005% w/v benzalkonium chloride. 19. The composition of claim 18, wherein the composition applied once daily lowers intraocular pressure as effectively as the second composition applied once daily. 20. The composition method of claim 18, wherein the composition applied once daily is effective for treating glaucoma.